The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Open accessAbstract
Alzheimer disease treatment has yet to yield a successful therapy that addresses the source of the damage found in brains. Of the varied proposed theories of AD etiology, reactive oxygen species (ROS) generation is cited as a common factor. Efforts to reduce the pathology associated with ROS via antioxidants therefore offer new hope to patients suffering from this devastative disease. Keywords: Antioxidant, calorie restriction, estrogen, free radical, glutathione, oxidation, oxidative stress, therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Further, although familial AD only accounts for a small percentage of AD cases, many have argued that mutations in AβPP and presenilin 1 and 2 are critical genetic factors in AD pathogenesis and in Aβ production [40,41].”
BackgroundOxidants, antioxidants, and the degenerative diseases of aging.
Ames, B. N., Shigenaga, M. K., & Hagen, T. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.7915 · Cited by 5,958
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“The physiological functions of these two proteins are unknown but may be involved in the Notch receptor pathway [57].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 2×
“Several major theories of AD, such as amyloid-beta (Aβ) toxicity [2], tauopathy [3], inflammation [4,5], oxidative stress [6–11], have all been represented broadly and argued intensely in the literature.”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“The majority (~70%) of early-onset familial AD cases are associated with mutations in two genes, presenilin 1 and presenilin 2, located on chromosomes 14 and 1, respectively [55].”
BackgroundOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“stantial evidence that oxidative stress is a cause, or at least the initial change, in the pathogenesis of AD [112].”
BackgroundSelf-citationAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“A PP transgenic mice treated with a Cu/Zn chelator showed improvement in general parameters and a reduction of brain A deposition [122].”
BackgroundInfluence of education and occupation on the incidence of Alzheimer's disease
Stern, Y. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370056032 · Cited by 1,434
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“AD was also found to be less frequent among individuals who used anti-inflammatory drugs [84].”
BackgroundStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 1×
“For example, polymorphisms are a determinant of brain Aβ burden in individuals affected with AD [44,45].”
BackgroundApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias
Plassman, B. L., Havlik, R. J., Steffens, D. C., Helms, M. J., Newman, T. N., Drosdick, D., Phillips, C., Gau, B. A., Welsh–Bohmer, K. A., Burke, J. R., et al. (2000) · Neurology · doi:10.1212/wnl.55.8.1158 · Cited by 896 · cited 1×
“• Traumatic head injury is associated with increased risk of AD [70].”
BackgroundCannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 1×
“In addition, cannabidiol is more effective than either vitamin C or E in protecting against glutamate neurotoxicity [171].”
BackgroundCalorie restriction–the SIR2 connection
Guarente, L., & Picard, F. (2005) · Cell · doi:10.1016/j.cell.2005.01.029 · Cited by 793 · cited 1×
“The development of chemical mimics for caloric restriction, such as resveratrol and sirtuins, the nicotinamide adenine dinucleotide dependent protein deacetylases [136,137], may make caloric restriction for normal people more easily attainable in the future.”
BackgroundCu(II) Potentiation of Alzheimer Aβ Neurotoxicity
Huang, X., Cuajungco, M. P., Atwood, C. S., Hartshorn, M. A., Tyndall, J. D. A., Hanson, G. R., Stokes, K. C., Leopold, M., Multhaup, G., Goldstein, L. E., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37111 · Cited by 762
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678 · cited 1×
“Results showed that there is a significant difference in the incidence of AD between those taking vitamin E and those who are not [145].”
BackgroundVascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Perry, G., Friedman, R., Shaw, G., & Chau, V (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3033 · Cited by 623
Self-citationSeshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D'Agostino, R. B. (1997) · Neurology · doi:10.1212/wnl.49.6.1498 · Cited by 489 · cited 1×
“The risk of AD varies from 12% to 19% for women over the age of 65 years and 6% to 10% for men [12] and rises exponentially with age, such that up to 47% of individuals over the age of 80 develop AD [13].”
BackgroundZhu, X., Rottkamp, C. A., Boux, H., Takeda, A., Perry, G., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.10.880 · Cited by 378 · cited 1×
“Consistent with this notion, tau phosphorylation and aggregation and NFT epitopes have been shown experimentally to be consequences of both oxidative stress and post-translational oxidation of tau [26,28,63-66].”
BackgroundSelf-citationReflections on the Discovery and Significance of Estrogen Receptor β
Koehler, K. F., Helguero, L. A., Haldosén, L.-A., Warner, M., & Gustafsson, J.-A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0027 · Cited by 360
Dietary Restriction Benefits Learning and Motor Performance of Aged Mice
Ingram, D. K., Weindruch, R., Spangler, E. L., Freeman, J. R., & Walford, R. L. (1987) · Journal of Gerontology · doi:10.1093/geronj/42.1.78 · Cited by 342
Dubey, A., Forster, M. J., Lal, H., & Sohal, R. S. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0380 · Cited by 289
Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron
Honda, K., Smith, M. A., Zhu, X., Baus, D., Merrick, W. C., Tartakoff, A. M., Hattier, T., Harris, P. L., Siedlak, S. L., Fujioka, H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500526200 · Cited by 280
Self-citationYamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T., & Nabeshima, T. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00408.x · Cited by 238
Gutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162 · cited 1×
“In two large clinical studies, administration of idebenone, a compound structurally similar to ubiquinone, has been reported to significantly reduce disease progression in a dosedependent fashion [165,166].”
BackgroundIdebenone treatment fails to slow cognitive decline in Alzheimer’s disease
Thal, L. J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M. F., Zamrini, E., & Thomas, R. G. (2003) · Neurology · doi:10.1212/01.wnl.0000096376.03678.c1 · Cited by 156
A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease
Weyer, G., Babej-Dölle, R. M., Hadler, D., Hofmann, S., & Herrmann, W. M. (2008) · Neuropsychobiology · doi:10.1159/000119366 · Cited by 120 · cited 1×
“In two large clinical studies, administration of idebenone, a compound structurally similar to ubiquinone, has been reported to significantly reduce disease progression in a dosedependent fashion [165,166].”
BackgroundEidenmüller, J., Fath, T., Hellwig, A., Reed, J., Sontag, E., & Brandt, R. (2000) · Biochemistry · doi:10.1021/bi001290z · Cited by 117 · cited 2×
“The resistance to proteolytic degradation of hyperphosphorylated tau may play a key role in neurofibrillary degeneration in AD patients [32,33].”
BackgroundGutzmann, H., Kühl, K.-P., Hadler, D., & Rapp, M. A. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-19833 · Cited by 85
Cited by
Lipid peroxidation: Physiological levels and dual biological effects
Niki, E. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.032 · Cited by 1,006
Neuroprotective Effects of Quercetin in Alzheimer’s Disease
Khan, H., Ullah, H., Aschner, M., Cheang, W. S., & Akkol, E. K. (2019) · Biomolecules · doi:10.3390/biom10010059 · Cited by 537
Ferulic acid: A review of its pharmacology, pharmacokinetics and derivatives
Li, D., Rui, Y.-X., Guo, S.-D., Luan, F., Liu, R., & Zeng, N. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119921 · Cited by 506
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Metadata
- Authors
- Aliev, G., Obrenovich, M., Reddy, V., Shenk, J., Moreira, P., Nunomura, A., Zhu, X., Smith, M., & Perry, G.
- Venue
- Mini-Reviews in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-11-01
- Volume
- 8
- Issue
- 13
- Pages
- 1395-1406
- ISSN
- 1389-5575 (ISSN-L)
- OpenAlex
- W2114334959
- Cited by
- 159
- References
- 38
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.